CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
Dexmedetomidinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00697788
NCT00697788Phase 2Completed
CompareCT.gov

Cardiovascular Safety of Dexmedetomidine in Pediatric Burn Patients.

Massachusetts General Hospital·interventional·Posted Jun 16, 2008·Updated Jul 17, 2017

In Brief

A Phase 2 clinical trial evaluating Dexmedetomidine for Burns and Sedation. Completed, enrolled 8 participants across 1 site.

Detailed Summary

Dexmedetomidine is a sedative drug approved for adult patients, intubated, in intensive care units. We are studying whether this drug is cardiovascularly safe in pediatric patients who have recently been burned.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBurns, Sedation
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 16, 2008
Enrollment StartJul 16, 2007
Primary CompletionDec 30, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 18.0 years ago

Interventions

Dexmedetomidinedrug

Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine \[in ug/kg/hr\], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.